NCT06548529View on ClinicalTrials.gov

HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
HER2 Positive or Suspicious Positive Tumors
Interventions
RADIATION

HER2 expression of PET imaging

Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC

Trial Locations (1)

Unknown

RECRUITING

uEXPLORER total-body PET/CT scanner (United Imaging, China), Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER